MedTrace Logo

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

NCT00809276 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2015-02-16

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.

Conditions

Interventions

DRUG

Busulfan, Fludarabine, Cytoxan

Busulfan once a day for 4 days Fludarabine once a day for 4 days Bone marrow transplant Cytoxan two doses

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • Fred Hutchinson Cancer Center

    collaborator OTHER

  • Otsuka Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Leo Luznik, MD · Johns Hopkins University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00809276 on ClinicalTrials.gov